Author Index

Search or browse for an author across our entire electronic archive

Search results for: O
Results 211 - 220 of 696 shown below

  • Ogura, M

    J Liu, H Harada, M Ogura, T Shibata and M Hiraoka

    Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts

    advance online publication, 2007-05-22 00:00:00.000;

    doi:10.1038/sj.bjc.6603812

    Abstract | Full article | PDF

  • Ogura, S

    H Asahina, K Yamazaki, I Kinoshita, N Sukoh, M Harada, H Yokouchi, T Ishida, S Ogura, T Kojima, Y Okamoto, Y Fujita, H Dosaka–akita, H Isobe and M Nishimura

    A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

    doi:10.1038/sj.bjc.6603393

    Abstract | Full article | PDF

  • F Hommura, H Dosaka-Akita, I Kinoshita, T Mishina, H Hiroumi, S Ogura, H Katoh and Y Kawakami

    Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers

    doi:10.1038/sj.bjc.6690750

    Abstract | Full article | PDF

  • Ogura, Y

    S Hazama, T Noma, F Wang, N Iizuka, Y Ogura, K Yoshimura, E Inoguchi, M Hakozaki, K Hirose, T Suzuki and M Oka

    Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo

    doi:10.1038/sj.bjc.6690538

    Abstract | Full article | PDF

  • Oh, B-H

    I-K Kim, Y-K Jung, D-Y Noh, Y-S Song, C-H Choi, B-H Oh, E S Masuda and Y-K Jung

    Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2

    doi:10.1038/sj.bjc.3298-02mp

    Abstract | Full article | PDF

  • I-K Kim, Y-K Jung, D-Y Noh, Y-S Song, C-H Choi, B-H Oh, E S Masuda and Y-K Jung

    Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2

    doi:10.1038/sj.bjc.6600795

    Abstract | Full article | PDF

  • Oh, D S

    P K Julka, R T Chacko, S Nag, R Parshad, A Nair, D S Oh, Z Hu, C B Koppiker, S Nair, R Dawar, N Dhindsa, I D Miller, D Ma, B Lin, B Awasthy and C M Perou

    A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling

    advance online publication, 2008-04-01 00:00:00.000;

    doi:10.1038/sj.bjc.6604322

    Abstract | Full article | PDF

  • Oh, D-Y

    D-W Kim, H S Min, K-H Lee, Y J Kim, D-Y Oh, Y K Jeon, S-H Lee, S-A Im, D H Chung, Y T Kim, T-Y Kim, Y-J Bang, S W Sung, J H Kim and D S Heo

    High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer

    advance online publication, 2008-02-19 00:00:00.000;

    doi:10.1038/sj.bjc.6604256

    Abstract | Full article | PDF

  • S-W Han, D-Y Oh, S-A Im, S R Park, K-W Lee, H S Song, N-S Lee, K H Lee, I S Choi, M H Lee, M A Kim, W H Kim, Y-J Bang and T-Y Kim

    Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

    advance online publication, 2009-01-06 00:00:00.000;

    doi:10.1038/sj.bjc.6604861

    Abstract | Full article | PDF

  • Oh, Do-Youn

    J W Kim, S-J Kim, Y-H Chung, J-H Kwon, H-J Lee, Y-J Chung, Y J Kim, Do-Youn Oh, S-H Lee, D-W Kim, S-A Im, T-Y Kim, D S Heo and Y-J Bang

    Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives

    doi:10.1038/sj.bjc.6604750

    Abstract | Full article | PDF

  • Oh, S

    B J Stish, S Oh, H Chen, A Z Dudek, R A Kratzke and D A Vallera

    Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity

    doi:10.1038/sj.bjc.6605297

    Abstract | Full article | PDF

  • Oh, S C

    S C Oh, K H Park, I K Choi, S Y Yoon, S J Kim, J H Seo, C W Choi, B S Kim, S W Shin, J S Kim and Y H Kim

    Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer

    advance online publication, 2005-02-22 00:00:00.000;

    doi:10.1038/sj.bjc.6602446

    Abstract | Full article | PDF

  • S C Oh, H Y Sur, H J Sung, I K Choi, S S Park, J H Seo, Y T Jeen, H J Chun, S W Shin, Y J Mok, J S Kim and Y H Kim

    A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer

    advance online publication, 2007-05-01 00:00:00.000;

    doi:10.1038/sj.bjc.6603752

    Abstract | Full article | PDF

  • Oh, S T

    H J Kang, H M Chang, T W Kim, M-H Ryu, H J Sohn, J H Yook, S T Oh, B S Kim, J-S Lee and Y-K Kang

    Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy

    advance online publication, 2005-01-18 00:00:00.000;

    doi:10.1038/sj.bjc.6602336

    Abstract | Full article | PDF

  • H J Kang, H M Chang, T W Kim, M-H Ryu, H-J Sohn, J H Yook, S T Oh, B S Kim, J-S Lee and Y-K Kang

    A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

    advance online publication, 2008-01-22 00:00:00.000;

    doi:10.1038/sj.bjc.6604186

    Abstract | Full article | PDF